Brexpiprazole: A new option in treating agitation in Alzheimer's dementia-Insights from transgenic mouse models

• Päätekijät: Naoki Amada (Tekijä), Shinji Sato (Tekijä), Dai Ishikawa (Tekijä), Mai Nakamura (Tekijä), Mikio Suzuki (Tekijä), Takashi Futamura (Tekijä), Kenji Maeda (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2024-09-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Aim Brexpiprazole is the first FDA‐approved treatment for agitation associated with dementia due to Alzheimer's disease. Agitation in Alzheimer's dementia (AAD) occurs in high prevalence and is a great burden for patients and caregivers. Efficacy, safety, and tolerability of brexp...